Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 9/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31037096 | 0.83 | CA9 (0.46) | KHKCNR2CA9PTGS2ABHD16A | |
| SCHEMBL31037064 | 0.82 | CA9 (0.45) | KHKCNR2CA9PTGS2ABHD16A | |
| SCHEMBL2547130 | 0.81 | KHK (0.58) | KHK | |
| SCHEMBL2547135 | 0.76 | KHK (0.57) | KHKL3MBTL1 | |
| SCHEMBL2546328 | 0.76 | KHK (0.57) | KHKCA9CA12 | |
| SCHEMBL31037047 | 0.74 | PTPRC (0.47) | CA9PTGS2ABHD16ACA12ACHE | |
| SCHEMBL7114374 | 0.73 | ALDH1A1 (0.52) | FGFR1CNR2CA9PTGS2L3MBTL1 | |
| SCHEMBL3649707 | 0.73 | L3MBTL1 (0.50) | FGFR1CNR2CA9PTGS2L3MBTL1 | |
| SCHEMBL29369460 | 0.73 | ALDH1A1 (0.53) | CA9PTGS2F2PLAUELANE | |
| SCHEMBL14910318 | 0.72 | CNR2 (0.62) | CNR2L3MBTL1F2PLAUKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771375-B2 | Indazole compounds useful as ketohexokinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-26 | — | — | US | disclosed |
| EP-2560962-B1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-20140336170-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-11-13 | — | — | US | disclosed |
| US-8822447-B2 | Indazole compounds useful as ketohexokinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-02 | — | — | US | disclosed |
| US-20110263559-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336170-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | KHK, GCK, GCKR | KHK 1/4885FGFR1 2128/4885CNR2 1675/4885 |
| US-20110263559-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | KHK, GCK, GCKR | KHK 1/4885FGFR1 2128/4885CNR2 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.